Details for Patent: 10,188,663
✉ Email this page to a colleague
Which drugs does patent 10,188,663 protect, and when does it expire?
Patent 10,188,663 protects FULVESTRANT and is included in one NDA.
Summary for Patent: 10,188,663
| Title: | Fulvestrant formulations |
| Abstract: | The invention provides a fulvestrant composition comprising not more than 2% total impurities that comprises a nonionic surfactant and/or a ricinoleate vehicle and which, optionally, is free of a non-aqueous ester solvent. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject. |
| Inventor(s): | Faraj; Jabar A. (Birmingham, AL) |
| Assignee: | Fresenius Kabi USA, LLC (Lake Zurich, IL) |
| Application Number: | 15/799,281 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,188,663
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fresenius Kabi Usa | FULVESTRANT | fulvestrant | SOLUTION;INTRAMUSCULAR | 210326-001 | May 20, 2019 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | TREATMENT OF HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
